

1. Cohen EEW, **Licitra LF**, Burtness B, Fayette J, Gauler T, Clement PM, Grau JJ, Del Campo JM, Mailliez A, Haddad RI, Vermorken JB, Tahara M, Guigay J, Geoffrois L, Merlano MC, Dupuis N, Krämer N, Cong XJ, Gibson N, Solca F, Ehrnrooth E, Machiels JH. "Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer." *Ann Oncol.* 2017 Oct 1;28(10):2526-2532. doi: 10.1093/annonc/mdx344. PMID: 28961833 [Free Article](#)
2. Specenier PM, Remenar E, Buter J, Schrijvers DL, Bergamini C, **Licitra LF**, Awada A, Clement PM, Fortpied C, Menis J, Vermorken JB. "TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial." *Ann Oncol.* 2017 Sep 1;28(9):2219-2224. doi: 10.1093/annonc/mdx300. PMID: 28911062
3. Basset-Séguin N, Hauschild A, Kunstfeld R, Grob J, Dréno B, Mortier L, Ascierto PA, **Licitra L**, Dutriaux C, Thomas L, Meyer N, Guillot B, Dummer R, Arenberger P, Fife K, Raimundo A, Dika E, Dimier N, Fittipaldo A, Xynos I, Hansson J." Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial" *Eur J Cancer.* 2017 Oct 23;86:334-348. doi: 10.1016/j.ejca.2017.08.022. PMID: 29073584 [Free Article](#)
4. Schlumberger M, Elisei R, Müller S, Schöffski P, Brose M, Shah M, **Licitra L**, Krajewska J, Kreissl MC, Niederle B, Cohen EEW, Wirth L, Ali H, Clary DO, Yaron Y, Mangeshkar M, Ball D, Nelkin B, Sherman S. "Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma" *Ann Oncol.* 2017 Nov 1;28(11):2813-2819. doi: 10.1093/annonc/mdx479 PMID: 29045520
5. Ascierto PA, Daniele B, Hammers H, Hirsh V, Kim J, **Licitra L**, Nanda R, Pignata S. "Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016" *J Transl Med.* 2017 Oct 11;15(1):205. doi: 10.1186/s12967-017-1309-2-PMID 29020960
6. Members of EORTC QAC; Working Groups of Scientific Experts "Multidisciplinary quality assurance and control in oncological trials: Perspectives from European Organisation for Research and Treatment of Cancer (EORTC)" *Eur J Cancer.* 2017 Sep 29;86:91-100. doi: 10.1016/j.ejca.2017.07.039 - PMID: 28964907
7. Resteghini C, Cavalieri S, Galbiati D, Granata R, Alfieri S, Bergamini C, Bossi P, **Licitra L**, Locati LD "Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients" *Best Pract Res Clin Endocrinol Metab.* 2017 Jun;31(3):349-361. doi: 10.1016/j.beem.2017.04.012. Epub 2017 May 10. Review PMID 28911730
8. Bossi P, Miceli R, Locati LD, Ferrari D, Vecchio S, Moretti G, Denaro N, Caponigro F, Airolidi M, Moro C, Vaccher E, Sponghini A, Caldara A, Rinaldi G, Ferrau F, Nolè F, Lo Vullo S, Tettamanzi F, Hollander L, **Licitra L** "A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck" *Ann Oncol.* 2017 Nov 1;28(11):2820-2826. doi: 10.1093/annonc/mdx439 PMID: 28950305
9. C. Resteghini, L. D. Locati, P. Bossi, C. Bergamini, M. Guzzo, **L. Licitra** Do not throw the baby out with the bathwater: SELECT a personalized, de-escalated lenvatinib schedule allows response in locally advanced DTC while controlling major drug-related bleeding. *Ann Oncol mdx251.* DOI:<https://doi.org/10.1093/annonc/mdx251> Published: 19 July 2017 PMID: 28911079.
10. Alfieri S, Iacovelli NA, Marceglia S, Lasorsa I, Resteghini C, Taverna F, Mazzocchi A, Orlandi E, Guzzo M, Bianchi R, Fanti D, Pala L, Racca S, Dvir R, Quattrone P, Gloghini A, Volpi CC, Granata R, Bergamini C, Locati L, **Licitra L**, Bossi P. [Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area.](#) *Oncotarget.* 2017 Jul 18;8(29):47780-47789. doi: 10.18632/oncotarget.17822 - PMID:28562354 [Free Article](#)
11. Harrington KJ, Ferris RL, Blumenschein G Jr, Colevas AD, Fayette J, **Licitra L**, Kasper S, Even C, Vokes EE, Worden F, Saba NF, Kiyota N, Haddad R, Tahara M, Grünwald V, Shaw JW<sup>6</sup>, Monga M, Lynch M, Taylor F, DeRosa M, Morrissey L, Cocks K, Gillison ML, Guigay J "Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial." *Lancet Oncol.* 2017 Aug;18(8):1104-1115. doi: 10.1016/S1470-2045(17)30421-7. Epub 2017 Jun 23. PMID:28651929

12. Psyrri A, Fortpied C, Koutsodontis G, Avgeris M, Kroupis C, Goutas N, Menis J, Herman L, Giurgea L, Remenar E, Degardin M, Pateras IS, Langendijk JA, van Herpen C, Awada A, Germà-Lluch JR, Kienzer HR, **Licitra L**, Vermorken JB. - Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: A subset analysis of EORTC 24971 study - *Ann Oncol.* 2017 Jun 23. doi: 10.1093/annonc/mdx320. [Epub ahead of print] PMID: 28651338
13. Szturz P, Wouters K, Kiyota N, Tahara M, Prabhash K, Noronha V, Castro A, **Licitra L**, Adelstein D, Vermorken JB. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data - *Oncologist.* 2017 May 22. pii: theoncologist.2017-0015. doi: 10.1634/theoncologist.2017-0015. [Epub ahead of print] PMID: 28533474
14. Luca Tonella, Marco Giannoccaro, Salvatore Alfieri, Silvana Canevari, Loris De Cecco - Head and Neck Cancer (L **Licitra**, Section Editor) Gene Expression Signatures for Head and Neck Cancer Patient Stratification: Are Results Ready for Clinical Application? 2017 May DOI: 10.1007/s11864-017-0472-2 – PubMed PMID 28474265
15. Argiris A, Harrington KJ, Tahara M, Schulten J, Chomette P, Ferreira Castro A, **Licitra L**. Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. *Front Oncol.* 2017 May 9;7:72. doi: 10.3389/fonc.2017.00072. eCollection 2017. Review.PMID: 28536670 [Free PMC Article](#)
16. Petr Szturz, KRISTIEN WOUTERS, Naomi Kiyota, Makoto Tahara, Kumar Prabhash, vanita noronha, Ana Castro, **LISA LICITRA**, DAVID J ADELSTEIN, J.B. VERMORKEN [Weekly low-dose versus three-weekly high-dose cisplatin for concurrent chemoradiation in locoregionally advanced non-nasopharyngeal head and neck cancer: a systematic review and meta-analysis of aggregate data.](#) DOI:10.1634/ /onco.12158 Internal Article ID: 14165279
17. Siano M, Infante G, Resteghini C, Cau MC, Alfieri S, Bergamini C, Granata R, Miceli R, Locati L, **Licitra L**, Bossi P. Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy. - *Oral Oncol.* 2017 Jun;69:33-37. doi: 10.1016/j.oraloncology.2017.04.002. Epub 2017 Apr 9. PMID: 28559018
18. Meregaglia M, Cairns J, Alfieri S, Favales F, Mazzitelli D, Orlandi E, **Licitra L**, Bossi P. - [Eliciting Preferences for Clinical Follow-Up in Patients with Head and Neck Cancer Using Best-Worst Scaling.](#)- *Value Health.* 2017 Jun;20(6):799-808. doi: 10.1016/j.jval.2017.01.012. Epub 2017 Mar 31. PMID: 28577698
19. Alfieri S, Granata R, Bergamini C, Resteghini C, Bossi P, **Licitra LF**, Locati LD. Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm? *Oral Oncol.* 2017 Mar;66:58-63. doi: 10.1016/j.oraloncology.2016.12.016. Review. PubMed PMID: 28249649.
20. Singer S, Jordan S, Locati LD, Pinto M, Tomaszewska IM, Araujo C, Hammerlid E, Vidhubala E, Husson O, Kiyota N, Brannan C, Salem D, Gamper E, Arraras JI, Ioannidis G, Andry G, Inhestern J, Gregoire V, **Licitra L**. The EORTC module for quality of life in patients with thyroid cancer: phase III. *Endocr Relat Cancer.* 2017 Feb 21. pii: ERC-16-0530. doi: 10.1530/ERC-16-0530. [Epub ahead of print] PubMed PMID: 28223365.
21. Locati LD, Collini P, Imbimbo M, Barisella M, Testi A, **Licitra LF**, Löning T, Tiemann K, Quattrone P, Bimbatti E, Chiaravalli S, Casanova M, Tamborini E, Carta R, Gasparini P, Guzzo M, Massimino M, Ferrari A. Immunohistochemical and molecular profile of salivary gland cancer in children. *Pediatr Blood Cancer.* 2017 Jan 31. doi: 10.1002/pbc.26468. [Epub ahead of print] PubMed PMID: 28139061.
22. Soulières D, Faivre S, Mesía R, Remenár É, Li SH, Karpenko A, Dechaphunkul A, Ochsenreither S, Kiss LA, Lin JC, Nagarkar R, Tamás L, Kim SB, Erfán J, Alyasova A, Kasper S, Barone C, Turri S, Chakravartty A, Chol M, Aimone P, Hirawat S, **Licitra L**. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. *Lancet Oncol.* 2017 Mar;18(3):323-335. doi: 10.1016/S1470-2045(17)30064-5. PubMed PMID: 28131786.

23. De Cecco L, Giannoccaro M, Marchesi E, Bossi P, Favales F, Locati LD, **Licitra L**, Pilotti S, Canevari S. Integrative miRNA-Gene Expression Analysis Enables Refinement of Associated Biology and Prediction of Response to Cetuximab in Head and Neck Squamous Cell Cancer. **Genes** (Basel). 2017 Jan 14;8(1). pii: E35. doi: 10.3390/genes8010035. PubMed PMID: 28098823; PubMed Central PMCID: PMC5295029.
24. Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, **Licitra L**, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. **ESMO Open**. 2016 Sep 29;1(5):e000097. Review. PubMed PMID: 27843641; PubMed Central PMCID: PMC5070299.
25. Locati LD, Perrone F, Cortelazzi B, Bergamini C, Bossi P, Civelli E, Morosi C, Lo Vullo S, Imbimbo M, Quattrone P, Dagrada GP, Granata R, Resteghini C, Mirabile A, Alfieri S, Orlandi E, Mariani L, Saibene G, Pilotti S, **Licitra L**. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. **Eur J Cancer**. 2016 Dec;69:158-165. doi: 10.1016/j.ejca.2016.09.022. PubMed PMID: 27821319.
26. Bossi P, Bergamini C, Miceli R, Cova A, Orlandi E, Resteghini C, Locati L, Alfieri S, Imbimbo M, Granata R, Mariani L, Iacovelli NA, Huber V, Cavallo A, **Licitra L**, Rivoltini L. Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy. **Int J Radiat Oncol Biol Phys**. 2016 Dec 1;96(5):959-966. doi: 10.1016/j.ijrobp.2016.08.047. PubMed PMID: 27745982.
27. Pala L, Bergamini C, Imbimbo M, Granata R, Locati L, Alfieri S, **Licitra L**, Bossi P. Safety of combination treatment with imatinib mesylate, carboplatin, and cetuximab in a patient with multiple cancers: a case report. **Tumori**. 2016 Nov 11;102(Suppl. 2). doi: 10.5301/tj.5000485. PubMed PMID: 26979243.
28. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, **Licitra L**, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. **N Engl J Med**. 2016 Nov 10;375(19):1856-1867. PubMed PMID: 27718784.
29. Girelli L, Locati L, Galeone C, Scanagatta P, Duranti L, **Licitra L**, Pastorino U.- Lung metastasectomy in adenoid cystic cancer: Is it worth it? - Oral Oncol. 2017 Feb;65:114-118. doi: 10.1016/j.oraloncology.2016.10.018. Epub 2016 Oct 26. - PMID: 28341276
30. Spreafico A, Huang SH, Xu W, Granata R, Liu CS, Waldron JN, Chen E, Ringash J, Bayley A, Chan KK, Hope AJ, Cho J, Razak AA, Hansen A, Jang R, Perez-Ordóñez B, Weinreb I, Bossi P, Orlandi E, **Licitra LF**, Song Y, O'Sullivan B, Siu LL, Kim J. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. **Eur J Cancer**. 2016 Nov;67:174-182. doi: 10.1016/j.ejca.2016.08.013. PubMed PMID: 27669504.
31. Singer S, Husson O, Tomaszewska IM, Locati LD, Kiyota N, Scheidemann-Wesp U, Hofmeister D, Winterbotham M, Brannan C, Araújo C, Gamper EM, Kulis D, Rimmele H, Andry G, **Licitra L**. Quality-of-Life Priorities in Patients with Thyroid Cancer: A Multinational European Organisation for Research and Treatment of Cancer Phase I Study. **Thyroid**. 2016 Nov;26(11):1605-1613. PubMed PMID: 27605136.
32. Reich M, **Licitra L**, Vermorken JB, Bernier J, Parmar S, Golusinski W, Castellsagué X, Leemans CR. Best practice guidelines in the psychosocial management of HPV-related head and neck cancer: recommendations from the European Head and Neck Cancer Society's Make Sense Campaign. **Ann Oncol**. 2016 Oct;27(10):1848-54. doi: 10.1093/annonc/mdw272. Review. PubMed PMID: 27456297.

33. Lacouture ME, Dréno B, Ascierto PA, Dummer R, Basset-Seguín N, Fife K, Ernst S, **Licitra L**, Neves RI, Peris K, Puig S, Sokolof J, Sekulic A, Hauschild A, Kunstfeld R. Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma. **Oncologist**. 2016 Oct;21(10):1218-1229. Review. PubMed PMID: 27511905; PubMed Central PMCID: PMC5061532.
34. Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, **Licitra L**, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. **ESMO Open**. 2016 Sep 29;1(5):e000097. Review. PubMed PMID: 27843641; PubMed Central PMCID: PMC5070299.
35. Henriques De Figueiredo B, Fortpied C, Menis J, Lefebvre JL, Barzan L, de Raucourt D, Geoffrois L, Giurgea L, Hupperets P, Leemans CR, **Licitra L**, Rolland F, Tesselaar M, Vermorken JB, Grégoire V; EORTC Head and Neck Cancer and Radiation Oncology Cooperative Groups.. Long-term update of the 24954 EORTC phase III trial on larynx preservation. **Eur J Cancer**. 2016 Sep;65:109-12. doi: 10.1016/j.ejca.2016.06.024. PubMed PMID: 27494036.
36. Bossi P, Resteghini C, Paielli N, **Licitra L**, Pilotti S, Perrone F. Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma. **Oncotarget**. 2016 Aug 19. doi: 10.18632/oncotarget.11413.
37. Clement PM, Gauler T, Machiels JP, Haddad RI, Fayette J, **Licitra LF**, Tahara M, Cohen EE, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G Jr, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Vermorken JB; LUX-H&N 1 investigators.. Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial. **Ann Oncol**. 2016 Aug;27(8):1585-93. doi: 10.1093/annonc/mdw151. PubMed PMID: 27084954; PubMed Central PMCID: PMC4959921.
38. Bossi P, Bergamini C, Siano M, Cossu Rocca M, Sponghini AP, Favales F, Giannoccaro M, Marchesi E, Cortelazzi B, Perrone F, Pilotti S, Locati LD, **Licitra L**, Canevari S, De Cecco L. Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab. **Clin Cancer Res**. 2016 Aug 1;22(15):3961-70. doi: 10.1158/1078-0432.CCR-15-2547. PubMed PMID: 26920888.
39. Sanguineti G, **Licitra L**. How Much of the Future Can Be Read Through the Skin? **Int J Radiat Oncol Biol Phys**. 2016 Aug 1;95(5):1355-6. doi: 10.1016/j.ijrobp.2016.05.015. PubMed PMID: 27479722.
40. **Licitra L**, Keilholz U, Tahara M, Lin JC, Chomette P, Ceruse P, Harrington K, Mesia R. Evaluation of the benefit and use of multidisciplinary teams in the treatment of head and neck cancer. **Oral Oncol**. 2016 Aug;59:73-9. doi: 10.1016/j.oraloncology.2016.06.002. Review. PubMed PMID: 27424185.
41. Alterio D, Franco P, Numico G, **Licitra L**, Cossu Rocca M, Ferrari A, Pinto C, Russi EG, Ricardi U, Jereczek Fossa BA. Non-surgical organ preservation strategies for locally advanced laryngeal tumors: what is the Italian attitude? Results of a national survey on behalf of AIRO and AIOM. **Med Oncol**. 2016 Jul;33(7):76. doi: 10.1007/s12032-016-0781-5. PubMed PMID: 27290695.
42. Perrone F, Bossi P, Cortelazzi B, Dagrada GP, Paielli N, **Licitra L**, Pilotti S. Absence of ALK and MET alterations in head and neck sarcomatoid carcinoma. **Oral Oncol**. 2016 Jul;58:e4-5. doi: 10.1016/j.oraloncology.2016.05.015. PubMed PMID: 27262592.
43. Locati LD, Perrone F, Cortelazzi B, Lo Vullo S, Bossi P, Dagrada G, Quattrone P, Bergamini C, Potepan P, Civelli E, Fallai C, Pilotti S, **Licitra L**. Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers. **Head Neck**. 2016 May;38(5):724-31. doi: 10.1002/hed.23940. PubMed PMID: 25522335.

44. Alfieri S, Ripamonti CI, Marcegaglia S, Orlandi E, Iacovelli NA, Granata R, Cavallo A, Pozzi P, Boffi R, Bergamini C, Imbimbo M, Pala L, Resteghini C, Mirabile A, Locati LD, **Licitra L**, Bossi P. Temporal course and predictive factors of analgesic opioid requirement for chemoradiation-induced oral mucositis in oropharyngeal cancer. **Head Neck**. 2016 Apr;38 Suppl 1:E1521-7. doi: 10.1002/hed.24272. PubMed PMID: 26849016.
45. Mirabile A, Vismara C, Crippa F, Bossi P, Locati L, Bergamini C, Granata R, Resteghini C, Conte E, Morelli D, Scarpellini P, **Licitra L**. Health care-associated infections in patients with head and neck cancer treated with chemotherapy and/or radiotherapy. **Head Neck**. 2016 Apr;38 Suppl 1:E1009-13. doi: 10.1002/hed.24147. PubMed PMID: 26041138.
46. Mirabile A, Airoidi M, Ripamonti C, Bolner A, Murphy B, Russi E, Numico G, **Licitra L**, Bossi P. Pain management in head and neck cancer patients undergoing chemo-radiotherapy: Clinical practical recommendations. **Crit Rev Oncol Hematol**. 2016 Mar;99:100-6. doi: 10.1016/j.critrevonc.2015.11.010. Review. PubMed PMID: 26712589.
47. Bergamini C, Locati L, Bossi P, Granata R, Alfieri S, Resteghini C, Imbimbo M, Fallai C, Orlandi E, Tana S, Iacovelli NA, Guzzo M, Ibba T, Colombo S, Bianchi R, Pizzi N, Fontanella W, **Licitra L**. Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer? **Oral Oncol**. 2016 Mar;54:54-7. doi: 10.1016/j.oraloncology.2016.01.001. PubMed PMID: 26774920.
48. Schlumberger M, Jarzab B, Cabanillas ME, Robinson B, Pacini F, Ball DW, McCaffrey J, Newbold K, Allison R, Martins RG, **Licitra LF**, Shah MH, Bodenner D, Elisei R, Burmeister L, Funahashi Y, Ren M, O'Brien JP, Sherman SI. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. **Clin Cancer Res**. 2016 Jan 1;22(1):44-53. doi: 10.1158/1078-0432.CCR-15-1127. PubMed PMID: 26311725.
49. Ciccarese C, Alfieri S, Santoni M, Santini D, Brunelli M, Bergamini C, **Licitra L**, Montironi R, Tortora G, Massari F. New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. **Expert Opin Drug Metab Toxicol**. 2016;12(1):57-75. doi: 10.1517/17425255.2016.1120287. Review. PubMed PMID: 26565919.
50. **Licitra L**, Mesía R, Keilholz U. Individualised quality of life as a measure to guide treatment choices in squamous cell carcinoma of the head and neck. **Oral Oncol**. 2016 Jan;52:18-23. doi: 10.1016/j.oraloncology.2015.10.020. Review. PubMed PMID: 26578389.
51. Bossi P, Orlandi E, **Licitra L**. Comment on 'Impact of intra-arterial chemotherapy including internal carotid artery for advanced paranasal sinus cancers involving the skull base'. **Br J Cancer**. 2015 Dec 1;113(11):1638-9. doi: 10.1038/bjc.2015.293. PubMed PMID: 26263478; PubMed Central PMCID: PMC4705872.
52. Greco A, Orlandi E, Mirabile A, Takanen S, Fallai C, Iacovelli NA, Rimedio A, Russi E, Sala M, Monzani D, Rosenthal DI, Gunn GB, Steca P, **Licitra L**, Bossi P. Italian version of the M.D. Anderson Symptom Inventory--Head and Neck Module: linguistic validation. **Support Care Cancer**. 2015 Dec;23(12):3465-72. doi: 10.1007/s00520-015-2701-1. PubMed PMID: 25791393.
53. Schindler A, Denaro N, Russi EG, Pizzorni N, Bossi P, Merlotti A, Spadola Bissetti M, Numico G, Gava A, Orlandi E, Caspiani O, Buglione M, Alterio D, Bacigalupo A, De Sanctis V, Pavanato G, Ripamonti C, Merlano MC, **Licitra L**, Sanguineti G, Langendijk JA, Murphy B. Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus. **Crit Rev Oncol Hematol**. 2015 Nov;96(2):372-84. doi: 10.1016/j.critrevonc.2015.06.005. Review. PubMed PMID: 26141260.
54. Marta GN, Riera R, Bossi P, Zhong LP, **Licitra L**, Macedo CR, de Castro Junior G, Carvalho AL, William WN Jr, Kowalski LP. Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral cavity cancer patients: Systematic review and meta-analysis. **Eur J Cancer**. 2015 Nov;51(17):2596-603. doi: 10.1016/j.ejca.2015.08.007. Review. PubMed PMID: 26318725.
55. Russi EG, Moretto F, Rampino M, Benasso M, Bacigalupo A, De Sanctis V, Numico G, Bossi P, Buglione M, Lombardo A, Airoidi M, Merlano MC, **Licitra L**, Denaro N, Pergolizzi S, Pinto C, Bensadoun RJ, Girolomoni G, Langendijk JA. Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: Literature review and consensus. **Crit Rev Oncol Hematol**. 2015 Oct;96(1):167-82. doi: 10.1016/j.critrevonc.2015.06.001. Review. PubMed PMID: 26187236.

56. Cortelazzi B, Verderio P, Ciniselli CM, Pizzamiglio S, Bossi P, Gloghini A, Gualeni AV, Volpi CC, Locati L, Pierotti MA, **Licitra L**, Pilotti S, Perrone F. Receptor tyrosine kinase profiles and human papillomavirus status in oropharyngeal squamous cell carcinoma. **J Oral Pathol Med**. 2015 Oct;44(9):734-45. doi: 10.1111/jop.12301. PubMed PMID: 25495427.
57. Pugliese DB, Bruzzesi G, Montaldo C, Porcu L, Landi M, Mastinu A, Torri V, **Licitra L**, Locati LD. Oral prevalence and clearance of oncogenic human papilloma virus in a rehabilitation community for substance abusers in Italy: a case of behavioral correction? **J Oral Pathol Med**. 2015 Oct;44(9):728-33. doi: 10.1111/jop.12291. PubMed PMID: 25401955.
58. Gatta G, Botta L, Sánchez MJ, Anderson LA, Pierannunzio D, **Licitra L**; EUROCARE Working Group.. Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study. **Eur J Cancer**. 2015 Sep 6. pii: S0959-8049(15)00749-2. doi: 10.1016/j.ejca.2015.07.043. PubMed PMID: 26421817.
59. Singer S, Araújo C, Arraras JI, Baumann I, Boehm A, Brokstad Herlofson B, Castro Silva J, Chie WC, Fisher S, Guntinas-Lichius O, Hammerlid E, Irrázaval ME, Jensen Hjermstad M, Jensen K, Kiyota N, **Licitra L**, Nicolatou-Galitis O, Pinto M, Santos M, Schmalz C, Sherman AC, Tomaszewska IM, Verdonck de Leeuw I, Yarom N, Zotti P, Hofmeister D; EORTC Quality of Life and the EORTC Head and Neck Cancer Groups.. Measuring quality of life in patients with head and neck cancer: Update of the EORTC QLQ-H&N Module, Phase III. **Head Neck**. 2015 Sep;37(9):1358-67. doi: 10.1002/hed.23762. PubMed PMID: 24832623.
60. Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, McCaffrey JC, Shah MH, Bodenner DL, Topliss D, Andresen C, O'Brien JP, Ren M, Funahashi Y, Allison R, Elisei R, Newbold K, **Licitra LF**, Sherman SI, Ball DW. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. **Cancer**. 2015 Aug 15;121(16):2749-56. doi: 10.1002/cncr.29395. PubMed PMID: 25913680; PubMed Central PMCID: PMC4803478.
61. Mirabile A, Numico G, Russi EG, Bossi P, Crippa F, Bacigalupo A, De Sanctis V, Musso S, Merlotti A, Ghi MG, Merlano MC, **Licitra L**, Moretto F, Denaro N, Caspiani O, Buglione M, Pergolizzi S, Cascio A, Bernier J, Raber-Durlacher J, Vermorken JB, Murphy B, Ranieri MV, Dellinger RP. Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensus. **Crit Rev Oncol Hematol**. 2015 Aug;95(2):191-213. doi: 10.1016/j.critrevonc.2015.03.003. Review. PubMed PMID: 25818202.
62. Roila F, Ruggeri B, Ballatori E, Fatigoni S, Caserta C, **Licitra L**, Mirabile A, Ionta MT, Massidda B, Cavanna L, Palladino MA, Tocci A, Fava S, Colantonio I, Angelelli L, Ciuffreda L, Fasola G, Zerilli F; Italian Group for Antiemetic Research.. Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study. **Ann Oncol**. 2015 Jun;26(6):1248-53. doi: 10.1093/annonc/mdv132. PubMed PMID: 25743855.
63. Basset-Seguín N, Hauschild A, Grob JJ, Kunstfeld R, Dréno B, Mortier L, Ascierto PA, **Licitra L**, Dutriaux C, Thomas L, Jouary T, Meyer N, Guillot B, Dummer R, Fife K, Ernst DS, Williams S, Fittipaldo A, Xynos I, Hansson J. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. **Lancet Oncol**. 2015 Jun;16(6):729-36. doi: 10.1016/S1470-2045(15)70198-1. PubMed PMID: 25981813.
64. Machiels JP, Haddad RI, Fayette J, **Licitra LF**, Tahara M, Vermorken JB, Clement PM, Gauler T, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G Jr, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Cohen EE; LUX-H&N 1 investigators.. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. **Lancet Oncol**. 2015 May;16(5):583-94. doi: 10.1016/S1470-2045(15)70124-5. PubMed PMID: 25892145.
65. Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, McCaffrey JC, Shah MH, Bodenner DL, Topliss D, Andresen C, O'Brien JP, Ren M, Funahashi Y, Allison R, Elisei R, Newbold K, **Licitra LF**, Sherman SI, Ball DW.- A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. - **Cancer**. 2015 Aug 15;121(16):2749-56. doi: 10.1002/cncr.29395. Epub 2015 Apr 24. PMID:25913680 - [Free PMC Article](#)

66. De Cecco L, Nicolau M, Giannoccaro M, Daidone MG, Bossi P, Locati L, **Licitra L**, Canevari S. Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data. **Oncotarget**. 2015 Apr 20;6(11):9627-42. PubMed PMID: 25821127; PubMed Central PMCID: PMC4496244.
67. Schechter RB, Nagilla M, Joseph L, Reddy P, Khattri A, Watson S, Locati LD, **Licitra L**, Greco A, Pelosi G, Carcangiu ML, Lingen MW, Seiwert TY, Cohen EE. Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy. **Cancer Lett**. 2015 Apr 10;359(2):269-74. doi: 10.1016/j.canlet.2015.01.024. PubMed PMID: 25641339.
68. Osman AA, Neskey DM, Katsonis P, Patel AA, Ward AM, Hsu TK, Hicks SC, McDonald TO, Ow TJ, Alves MO, Pickering CR, Skinner HD, Zhao M, Sturgis EM, Kies MS, El-Naggar A, Perrone F, **Licitra L**, Bossi P, Kimmel M, Frederick MJ, Lichtarge O, Myers JN. Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients. **Cancer Res**. 2015 Apr 1;75(7):1205-15. doi: 10.1158/0008-5472.CAN-14-2729. PubMed PMID: 25691460; PubMed Central PMCID: PMC4615655.
69. Bogaerts J, Sydes MR, Keat N, McConnell A, Benson A, Ho A, Roth A, Fortpied C, Eng C, Peckitt C, Coens C, Pettaway C, Arnold D, Hall E, Marshall E, Sclafani F, Hatcher H, Earl H, Ray-Coquard I, Paul J, Blay JY, Whelan J, Panageas K, Wheatley K, Harrington K, **Licitra L**, Billingham L, Hensley M, McCabe M, Patel PM, Carvajal R, Wilson R, Glynn-Jones R, McWilliams R, Leyvraz S, Rao S, Nicholson S, Filiaci V, Negrouk A, Lacombe D, Dupont E, Pauporté I, Welch JJ, Law K, Trimble T, Seymour M. Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. **Eur J Cancer**. 2015 Feb;51(3):271-81. doi: 10.1016/j.ejca.2014.10.027. Review. PubMed PMID: 25542058; PubMed Central PMCID: PMC4639696.
70. Pricl S, Cortelazzi B, Dal Col V, Marson D, Laurini E, Fermeglia M, **Licitra L**, Pilotti S, Bossi P, Perrone F. Smoothed (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. **Mol Oncol**. 2015 Feb;9(2):389-97. doi: 10.1016/j.molonc.2014.09.003. PubMed PMID: 25306392.
71. Calzavara Pinton P, **Licitra L**, Peris K, Santoro A, Ascierto PA. Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice. **Future Oncol**. 2015;11(9):1429-35. doi: 10.2217/fon.15.20. Review. PubMed PMID: 25952787.
72. Peris K, **Licitra L**, Ascierto PA, Corvò R, Simonacci M, Picciotto F, Gualdi G, Pellacani G, Santoro A. Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus. **Future Oncol**. 2015;11(4):703-12. doi: 10.2217/fon.14.281. Review. PubMed PMID: 25686123.
73. Buzzacchino S, Lanzola G, Bossi P, **Licitra L**, Quaglini S. A mobile application supporting outpatient treatment and follow-up. **Stud Health Technol Inform**. 2015;210:788-92. PubMed PMID: 25991262.
74. Proserpio T, Ferrari A, Lo Vullo S, Massimino M, Clerici CA, Veneroni L, Bresciani C, Casali PG, Ferrari M, Bossi P, Galmozzi G, Pierantozzi A, **Licitra L**, Marceglia S, Mariani L. Hope in cancer patients: the relational domain as a crucial factor. **Tumori**. 2015 Jul-Aug;101(4):447-54. doi: 10.5301/tj.5000366. PubMed PMID: 26045106.
75. Mitani Y, Rao PH, Maity SN, Lee YC, Ferrarotto R, Post JC, **Licitra L**, Lippman SM, Kies MS, Weber RS, Cautin C, Lin SH, El-Naggar AK. Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications. **Clin Cancer Res**. 2014 Dec 15;20(24):6570-81. doi: 10.1158/1078-0432.CCR-14-1746. PubMed PMID: 25316813; PubMed Central PMCID: PMC4268116.
76. **Licitra L**, Locati L. Antiangiogenic TKIs and advanced RAI-resistant thyroid cancer: time for rethinking treatment strategies? **Thyroid**. 2014 Dec;24(12):1815. doi: 10.1089/thy.2014.0288. PubMed PMID: 25180537.
77. Reich M, Leemans CR, Vermorken JB, Bernier J, **Licitra L**, Parmar S, Golusinski W, Lefebvre JL. Best practices in the management of the psycho-oncologic aspects of head and neck cancer patients: recommendations from the European Head and Neck Cancer Society Make Sense Campaign. **Ann Oncol**. 2014 Nov;25(11):2115-24. doi: 10.1093/annonc/mdu105. PubMed PMID: 24608199.
78. Orlandi E, Takanen S, Giandini T, Iannacone E, Fontanella W, Locati L, Carrara M, Bossi P, Bergamini C, Granata R, Tombolini V, Ibba T, **Licitra L**, Pignoli E, Fallai C. Postoperative radiotherapy with volumetric modulated arc therapy

- of lacrimal gland carcinoma: two case reports and literature review. **Future Oncol.** 2014 Nov;10(14):2111-20. doi: 10.2217/fon.14.148. PubMed PMID: 25471025.
79. Orlandi E, Giandini T, Iannacone E, De Ponti E, Carrara M, Mongioj V, Stucchi C, Tana S, Bossi P, **Licitra L**, Fallai C, Pignoli E. Radiotherapy for unresectable sinonasal cancers: dosimetric comparison of intensity modulated radiation therapy with coplanar and non-coplanar volumetric modulated arc therapy. **Radiother Oncol.** 2014 Nov;113(2):260-6. doi: 10.1016/j.radonc.2014.11.024. PubMed PMID: 25467003.
80. Granata R, Locati LD, **Licitra L**. Fosbretabulin for the treatment of anaplastic thyroid cancer. **Future Oncol.** 2014 Oct;10(13):2015-21. doi: 10.2217/fon.14.154. Review. PubMed PMID: 25396774.
81. Locati LD, **Licitra L**, Agate L, Ou SH, Boucher A, Jarzab B, Qin S, Kane MA, Wirth LJ, Chen C, Kim S, Ingrosso A, Pithavala YK, Bycott P, Cohen EE. Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. **Cancer.** 2014 Sep 1;120(17):2694-703. doi: 10.1002/cncr.28766. PubMed PMID: 24844950.
82. Bossi P, Locati L, Bergamini C, Mirabile A, Granata R, Imbimbo M, Resteghini C, **Licitra L**. Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer. **Oral Oncol.** 2014 Sep;50(9):884-7. doi: 10.1016/j.oraloncology.2014.06.013. PubMed PMID: 25001894.
83. De Cecco L, Bossi P, Locati L, Canevari S, **Licitra L**. Comprehensive gene expression meta-analysis of head and neck squamous cell carcinoma microarray data defines a robust survival predictor. **Ann Oncol.** 2014 Aug;25(8):1628-35. doi: 10.1093/annonc/mdu173. PubMed PMID: 24827125.
84. Machiels JP, **Licitra LF**, Haddad RI, Tahara M, Cohen EE. Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy. **BMC Cancer.** 2014 Jun 28;14:473. doi: 10.1186/1471-2407-14-473. PubMed PMID: 24973959; PubMed Central PMCID: PMC4079914.
85. Locati LD, Perrone F, Cortelazzi B, Imbimbo M, Bossi P, Potepan P, Civelli E, Rinaldi G, Quattrone P, **Licitra L**, Pilotti S. Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy. **Cancer Biol Ther.** 2014 Jun 1;15(6):678-82. doi: 10.4161/cbt.28410. PubMed PMID: 24618694; PubMed Central PMCID: PMC4049783.
86. Saloura V, Cohen EE, **Licitra L**, Billan S, Dinis J, Lisby S, Gauler TC. An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck. **Cancer Chemother Pharmacol.** 2014 Jun;73(6):1227-39. doi: 10.1007/s00280-014-2459-z. PubMed PMID: 24714973.
87. Vermorken JB, Psyrri A, Mesía R, Peyrade F, Beier F, de Blas B, Celik I, **Licitra L**. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. **Ann Oncol.** 2014 Apr;25(4):801-7. doi: 10.1093/annonc/mdt574. PubMed PMID: 24577117; PubMed Central PMCID: PMC3969553.
88. Bossi P, Orlandi E, Miceli R, Perrone F, Guzzo M, Mariani L, Granata R, Locati L, Fallai C, Cortelazzi B, Pilotti S, Scaramellini G, Gloghini A, **Licitra L**. Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis. **Ann Oncol.** 2014 Mar;25(3):694-9. doi: 10.1093/annonc/mdu004. PubMed PMID: 24510315; PubMed Central PMCID: PMC4433530.
89. Bossi P, Lo Vullo S, Guzzo M, Mariani L, Granata R, Orlandi E, Locati L, Scaramellini G, Fallai C, **Licitra L**. Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial. **Ann Oncol.** 2014 Feb;25(2):462-6. doi: 10.1093/annonc/mdt555. PubMed PMID: 24401930.
90. Bottomley A, Tridello G, Coens C, Rolland F, Tesselaar ME, Leemans CR, Hupperets P, **Licitra L**, Vermorken JB, Van Den Weyngaert D, Truc G, Barillot I, Lefebvre JL. An international phase 3 trial in head and neck cancer: quality of life and symptom results: EORTC 24954 on behalf of the EORTC Head and Neck and the EORTC Radiation Oncology Group. **Cancer.** 2014 Feb 1;120(3):390-8. doi: 10.1002/cncr.28392. PubMed PMID: 24452673.

91. Sosa JA, Elisei R, Jarzab B, Balkissoon J, Lu SP, Bal C, Marur S, Gramza A, Yosef RB, Gitlitz B, Haugen BR, Ondrey F, Lu C, Karandikar SM, Khuri F, **Licitra L**, Remick SC. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. **Thyroid**. 2014 Feb;24(2):232-40. doi: 10.1089/thy.2013.0078. PubMed PMID: 23721245.
92. Bossi P, Locati L, **Licitra L**. Emerging tyrosine kinase inhibitors for head and neck cancer. **Expert Opin Emerg Drugs**. 2013 Dec;18(4):445-59. doi: 10.1517/14728214.2013.842976. Review. PubMed PMID: 24094093.
93. Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, **Licitra L**, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Cabozantinib in progressive medullary thyroid cancer. **J Clin Oncol**. 2013 Oct 10;31(29):3639-46. doi: 10.1200/JCO.2012.48.4659. Erratum in: J Clin Oncol. 2014 Jun 10;32(17):1864. PubMed PMID: 24002501; PubMed Central PMCID: PMC4164813.
94. Bossi P, Kornek G, Lanzetta G, Rozzi A, Füreder T, Locati L, **Licitra L**. Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer. **Head Neck**. 2013 Oct;35(10):1471-4. doi: 10.1002/hed.23170. PubMed PMID: 23042567.
95. Orlandi E, Iannacone E, Fallai C, Bossi P, **Licitra L**. Comments on "postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: patterns of failure" by Chan and Coll. **Oral Oncol**. 2013 Oct;49(10):e38. doi: 10.1016/j.oraloncology.2012.12.015. PubMed PMID: 23375592.
96. Vermorken JB, **Licitra L**, Stöhlmacher-Williams J, Dietz A, Lopez-Picazo JM, Hamid O, Hossain AM, Chang SC, Gauler TC. Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck. **Eur J Cancer**. 2013 Sep;49(13):2877-83. doi: 10.1016/j.ejca.2013.05.002. PubMed PMID: 23726971.
97. Vermorken JB, Stöhlmacher-Williams J, Davidenko I, **Licitra L**, Winqvist E, Villanueva C, Foa P, Rottey S, Skladowski K, Tahara M, Pai VR, Faivre S, Blajman CR, Forastiere AA, Stein BN, Oliner KS, Pan Z, Bach BA; SPECTRUM investigators. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. **Lancet Oncol**. 2013 Jul;14(8):697-710. doi: 10.1016/S1470-2045(13)70181-5. PubMed PMID: 23746666.
98. Granata R, Locati L, **Licitra L**. Therapeutic strategies in the management of patients with metastatic anaplastic thyroid cancer: review of the current literature. **Curr Opin Oncol**. 2013 May;25(3):224-8. doi: 10.1097/CCO.0b013e32835ff44b. Review. PubMed PMID: 23493194.
99. Bossi P, Perrone F, Miceli R, Cantù G, Mariani L, Orlandi E, Fallai C, Locati LD, Cortelazzi B, Quattrone P, Potepan P, **Licitra L**, Pilotti S. Tp53 status as guide for the management of ethmoid sinus intestinal-type adenocarcinoma. **Oral Oncol**. 2013 May;49(5):413-9. doi: 10.1016/j.oraloncology.2012.12.011. PubMed PMID: 23369851.
100. **Licitra L**, Störkel S, Kerr KM, Van Cutsem E, Pirker R, Hirsch FR, Vermorken JB, von Heydebreck A, Esser R, Celik I, Ciardiello F. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. **Eur J Cancer**. 2013 Apr;49(6):1161-8. doi: 10.1016/j.ejca.2012.11.018. PubMed PMID: 23265711.
101. Borrello MG, Ardini E, Locati LD, Greco A, **Licitra L**, Pierotti MA. RET inhibition: implications in cancer therapy. **Expert Opin Ther Targets**. 2013 Apr;17(4):403-19. doi: 10.1517/14728222.2013.758715. Review. PubMed PMID: 23461584.
102. Carlson J, **Licitra L**, Locati L, Raben D, Persson F, Stenman G. Salivary gland cancer: an update on present and emerging therapies. **Am Soc Clin Oncol Educ Book**. 2013:257-63. doi: 10.1200/EdBook\_AM.2013.33.257. Review. PubMed PMID: 23714518.
103. Orlandi E, Tomatis S, Potepan P, Bossi P, Mongioj V, Carrara M, Palazzi M, Franceschini M, Bergamini C, Locati L, Iannacone E, Guzzo M, Ibba T, Crippa F, **Licitra L**, Pignoli E, Fallai C. Critical analysis of locoregional failures following intensity-modulated radiotherapy for nasopharyngeal carcinoma. **Future Oncol**. 2013 Jan;9(1):103-14. doi: 10.2217/fon.12.166. PubMed PMID: 23252567.

104. Bossi P, Resteghini C, Perrone F, Cortelazzi B, Pilotti S, Maurichi A, Locati LD, **Licitra L**. Prolonged response using gefitinib followed by sirolimus for advanced cutaneous squamous cell carcinoma. **J Am Acad Dermatol**. 2012 Nov;67(5):e226-8. doi: 10.1016/j.jaad.2012.04.029. PubMed PMID: 23062928.
105. Chan AT, Grégoire V, Lefebvre JL, **Licitra L**, Hui EP, Leung SF, Felip E; EHNS–ESMO–ESTRO Guidelines Working Group.. Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol**. 2012 Oct;23 Suppl 7:vii83-5. PubMed PMID: 22997460.
106. Urba S, van Herpen CM, Sahoo TP, Shin DM, **Licitra L**, Mezei K, Reuter C, Hitt R, Russo F, Chang SC, Hossain AM, Frimodt-Moller B, Koustenis A, Hong RL. Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study. **Cancer**. 2012 Oct 1;118(19):4694-705. doi: 10.1002/cncr.27449. PubMed PMID: 22434360.
107. **Licitra L**, Locati LD. Multikinase inhibitors in thyroid cancer. **Ann Oncol**. 2012 Sep;23 Suppl 10:x328-33. PubMed PMID: 22987985.
108. Andry G, Hamoir M, Locati LD, **Licitra L**, Langendijk JA. Management of salivary gland tumors. **Expert Rev Anticancer Ther**. 2012 Sep;12(9):1161-8. doi: 10.1586/era.12.92. Review. PubMed PMID: 23098116.
109. Granata R, Miceli R, Orlandi E, Perrone F, Cortelazzi B, Franceschini M, Locati LD, Bossi P, Bergamini C, Mirabile A, Mariani L, Olmi P, Scaramellini G, Potepan P, Quattrone P, Ang KK, **Licitra L**. Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study. **Ann Oncol**. 2012 Jul;23(7):1832-7. doi: 10.1093/annonc/mdr544. PubMed PMID: 22115925.
110. Liberato NL, Rognoni C, Rubrichi S, Quaglini S, Marchetti M, Gorlia T, **Licitra L**, Vermorken JB. Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost-utility analysis. **Ann Oncol**. 2012 Jul;23(7):1825-32. doi: 10.1093/annonc/mdr545. PubMed PMID: 22104577.
111. Mehanna H, Olaleye O, **Licitra L**. Oropharyngeal cancer - is it time to change management according to human papilloma virus status? **Curr Opin Otolaryngol Head Neck Surg**. 2012 Apr;20(2):120-4. doi: 10.1097/MOO.0b013e3283509735. Review. PubMed PMID: 22327790.
112. Van Dijk BA, Gatta G, Capocaccia R, Pierannunzio D, Strojan P, **Licitra L**; RARECARE Working Group.. Rare cancers of the head and neck area in Europe. **Eur J Cancer**. 2012 Apr;48(6):783-96. doi: 10.1016/j.ejca.2011.08.021. PubMed PMID: 22051735.
113. Locati LD, Bossi P, **Licitra L**. How many therapeutic options are there for recurrent or metastatic salivary duct carcinoma? **J Clin Oncol**. 2012 Feb 20;30(6):672; author reply 672-673. doi: 10.1200/JCO.2011.39.4577. PubMed PMID: 22253461.
114. Bossi P, Locati LD, **Licitra L**. Palifermin in prevention of head and neck cancer radiation-induced mucositis: not yet a definitive word on safety and efficacy profile. **J Clin Oncol**. 2012 Feb 10;30(5):564-5; 565-567. doi: 10.1200/JCO.2011.39.1136. PubMed PMID: 22215750.
115. Secondino S, Zecca M, **Licitra L**, Gurrado A, Schiavetto I, Bossi P, Locati L, Schiavo R, Basso S, Baldanti F, Maccario R, Locatelli F, Siena S, Pedrazzoli P, Comoli P. T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results. **Ann Oncol**. 2012 Feb;23(2):435-41. doi: 10.1093/annonc/mdr134. PubMed PMID: 21586688.
116. Carmeli B, Casali P, Goldbraich A, Goldsteen A, Kent C, **Licitra L**, Locatelli P, Restifo N, Rinott R, Sini E, Torresani M, Waks Z. Evicase: an evidence-based case structuring approach for personalized healthcare. **Stud Health Technol Inform**. 2012;180:604-8. PubMed PMID: 22874262.
117. Bossi P, Orlandi E, Bergamini C, Locati LD, Granata R, Mirabile A, Parolini D, Franceschini M, Fallai C, Olmi P, Quattrone P, Potepan P, Gloghini A, Miceli R, Mattana F, Scaramellini G, **Licitra L**. Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin

- in locally advanced EBV-related nasopharyngeal cancer. **Ann Oncol**. 2011 Nov;22(11):2495-500. doi: 10.1093/annonc/mdq783. PubMed PMID: 21398385.
118. Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, Otter R, **Licitra L**, Mallone S, Tavilla A, Trama A, Capocaccia R; RARECARE working group.. Rare cancers are not so rare: the rare cancer burden in Europe. **Eur J Cancer**. 2011 Nov;47(17):2493-511. doi: 10.1016/j.ejca.2011.08.008. PubMed PMID: 22033323.
119. **Licitra L**, Perrone F, Tamborini E, Bertola L, Ghirelli C, Negri T, Orsenigo M, Filipazzi P, Pastore E, Pompilio M, Bossi P, Locati LD, Cantu' G, Scaramellini G, Pilotti S, Tagliabue E. Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients. **Ann Oncol**. 2011 Aug;22(8):1886-93. doi: 10.1093/annonc/mdq756. PubMed PMID: 21343382.
120. Perrone F, Gloghini A, Cortelazzi B, Bossi P, **Licitra L**, Pilotti S. Isolating p16-positive/HPV-negative oropharyngeal cancer: an effort worth making. **Am J Surg Pathol**. 2011 May;35(5):774-7; author reply 777-8. doi: 10.1097/PAS.0b013e3182116a45. PubMed PMID: 21436677.
121. **Licitra L**, Mesia R, Rivera F, Remenár E, Hitt R, Erfán J, Rottey S, Kawecki A, Zabolotnyy D, Benasso M, Störkel S, Senger S, Stroh C, Vermorken JB. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. **Ann Oncol**. 2011 May;22(5):1078-87. doi: 10.1093/annonc/mdq588. PubMed PMID: 21048039; PubMed Central PMCID: PMC3082162.
122. **Licitra L**, Bergamini C, Mirabile A, Granata R. Targeted therapy in head and neck cancer. **Curr Opin Otolaryngol Head Neck Surg**. 2011 Apr;19(2):132-7. doi: 10.1097/MOO.0b013e328344b668. Review. PubMed PMID: 21372717.
123. Bossi P, Granata R, Bergamini C, Mirabile A, Locati L, **Licitra L**. Comment on "Acute toxicity of three versus two courses of cisplatin for radiochemotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN): a matched pair analysis", by Rades et coll. **Oral Oncol**. 2010 Dec;46(12):888; author reply 889-90. doi: 10.1016/j.oraloncology.2010.06.005. PubMed PMID: 20952248.
124. Psyrrri A, **Licitra L**, Lacombe D, Schuurin E, Budach W, Ozsahin M, Knecht R, Vermorken JB, Langendijk JA. Strategies to promote translational research within the European Organisation for Research and Treatment of Cancer (EORTC) Head and Neck Cancer Group: a report from the Translational Research Subcommittee. **Ann Oncol**. 2010 Oct;21(10):1952-60. doi: 10.1093/annonc/mdq060. Review. PubMed PMID: 20305037; PubMed Central PMCID: PMC2946861.
125. Chan AT, Grégoire V, Lefebvre JL, **Licitra L**, Felip E; EHNS-ESMO-ESTRO Guidelines Working Group.. Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol**. 2010 May;21 Suppl 5:v187-9. doi: 10.1093/annonc/mdq186. PubMed PMID: 20555078.
126. Grégoire V, Lefebvre JL, **Licitra L**, Felip E; EHNS-ESMO-ESTRO Guidelines Working Group.. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol**. 2010 May;21 Suppl 5:v184-6. doi: 10.1093/annonc/mdq185. PubMed PMID: 20555077.
127. Guzzo M, Locati LD, Prott FJ, Gatta G, McGurk M, **Licitra L**. Major and minor salivary gland tumors. **Crit Rev Oncol Hematol**. 2010 May;74(2):134-48. doi: 10.1016/j.critrevonc.2009.10.004. Review. PubMed PMID: 19939701.
128. Bernier J, **Licitra L**. Chemotherapy: Chemoradiation in head-and-neck cancer-are we any closer? **Nat Rev Clin Oncol**. 2010 May;7(5):247-9. doi: 10.1038/nrclinonc.2010.50. PubMed PMID: 20428220.
129. **Licitra L**, Locati LD, Greco A, Granata R, Bossi P. Multikinase inhibitors in thyroid cancer. **Eur J Cancer**. 2010 Apr;46(6):1012-8. doi: 10.1016/j.ejca.2010.01.010. PubMed PMID: 20171085.
130. Perrone F, Bossi P, Cortelazzi B, Locati L, Quattrone P, Pierotti MA, Pilotti S, **Licitra L**. TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. **J Clin Oncol**. 2010 Feb 10;28(5):761-6. doi: 10.1200/JCO.2009.22.4170. PubMed PMID: 20048189.

131. Fallai C, Perrone F, **Licitra L**, Pilotti S, Locati L, Bossi P, Orlandi E, Palazzi M, Olmi P. Oropharyngeal squamous cell carcinoma treated with radiotherapy or radiochemotherapy: prognostic role of TP53 and HPV status. **Int J Radiat Oncol Biol Phys**. 2009 Nov 15;75(4):1053-9. doi: 10.1016/j.ijrobp.2008.12.088. PubMed PMID: 19577857.
132. Locati LD, Perrone F, Losa M, Mela M, Casieri P, Orsenigo M, Cortelazzi B, Negri T, Tamborini E, Quattrone P, Bossi P, Rinaldi G, Bergamini C, Calderone RG, Liberatoscioli C, **Licitra L**. Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). **Oral Oncol**. 2009 Nov;45(11):986-90. doi: 10.1016/j.oraloncology.2009.05.635. PubMed PMID: 19574086.
133. Ciccolallo L, **Licitra L**, Cantù G, Gatta G; EUROCARE Working Group.. Survival from salivary glands adenoid cystic carcinoma in European populations. **Oral Oncol**. 2009 Aug;45(8):669-74. doi: 10.1016/j.oraloncology.2008.10.010. PubMed PMID: 19095489.
134. Palazzi M, Orlandi E, Bossi P, Pignoli E, Potepan P, Guzzo M, Franceschini M, Scaramellini G, Cantù G, **Licitra L**, Olmi P, Tomatis S. Further improvement in outcomes of nasopharyngeal carcinoma with optimized radiotherapy and induction plus concomitant chemotherapy: an update of the Milan experience. **Int J Radiat Oncol Biol Phys**. 2009 Jul 1;74(3):774-80. doi: 10.1016/j.ijrobp.2008.08.068. PubMed PMID: 19250771.
135. Locati LD, Bossi P, Perrone F, Potepan P, Crippa F, Mariani L, Casieri P, Orsenigo M, Losa M, Bergamini C, Liberatoscioli C, Quattrone P, Calderone RG, Rinaldi G, Pilotti S, **Licitra L**. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. **Oral Oncol**. 2009 Jul;45(7):574-8. doi: 10.1016/j.oraloncology.2008.07.010. PubMed PMID: 18804410.
136. **Licitra L**, Rolland F, Bokemeyer C, Remenar E, Kienzer H, Stoerkel S, Scheid S, Stroh C, Mesia R. Biomarker potential of EGFR gene copy number by FISH in the phase III EXTREME study: Platinum-based CT plus cetuximab in first-line R/M SCCHN. **J Clin Oncol**. 2009 May 20;27(15\_suppl):6005. PubMed PMID: 27962412.
137. Liberato NL, **Licitra L**, Bogaerts J, Danese G, Marchetti M, Quaglini S, Rognoni C, Rubrichi S, Vermorken JB. TPF versus PF as induction therapy in unresectable head and neck cancer: A pharmacoeconomic analysis. **J Clin Oncol**. 2009 May 20;27(15\_suppl):6075. PubMed PMID: 27961941.
138. Bossi P, Parolini D, Bergamini C, Locati LD, Orlandi E, Franceschini M, Palazzi M, Olmi P, Potepan P, **Licitra L**. TPF induction chemotherapy (CT) followed by concomitant cisplatin/radiotherapy (cCIRT) in locally advanced nasopharyngeal cancer (LANPC). **J Clin Oncol**. 2009 May 20;27(15\_suppl):6046. PubMed PMID: 27961922.
139. Vermorken JB, Stöhlmacher J, Davidenko I, Winkvist E, **Licitra L**, Pai VR, Skladowski K, Blajman CR, Faivre S, Gansert J. An analysis of safety in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) receiving chemotherapy (CT) with or without panitumumab (pmab) in a phase III clinical trial (SPECTRUM). **J Clin Oncol**. 2009 May 20;27(15\_suppl):6050. PubMed PMID: 27961915.
140. **Licitra L**, Felip E; ESMO Guidelines Working Group.. Squamous cell carcinoma of the head and neck: ESMO clinical recommendations for diagnosis, treatment and follow-up. **Ann Oncol**. 2009 May;20 Suppl 4:121-2. doi: 10.1093/annonc/mdp149. Review. PubMed PMID: 19454430.
141. Stewart JS, Cohen EE, **Licitra L**, Van Herpen CM, Khorprasert C, Soulieres D, Vodvarka P, Rischin D, Garin AM, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Hargreaves L, Armour A, Speake G, Swaisland A, Vokes EE. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. **J Clin Oncol**. 2009 Apr 10;27(11):1864-71. doi: 10.1200/JCO.2008.17.0530.
142. Lefebvre JL, Rolland F, Tessaar M, Bardet E, Leemans CR, Geoffrois L, Hupperets P, Barzan L, de Raucourt D, Chevalier D, **Licitra L**, Lunghi F, Stupp R, Lacombe D, Bogaerts J, Horiot JC, Bernier J, Vermorken JB; EORTC Head and Neck Cancer Cooperative Group.; EORTC Radiation Oncology Group.. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. **J Natl Cancer Inst**. 2009 Feb 4;101(3):142-52. doi: 10.1093/jnci/djn460. PubMed PMID: 19176454; PubMed Central PMCID: PMC2724854.
143. Psyrris A, Burtness B, Harari PM, Vermorken JB, **Licitra L**, Sasaki CT. Head and neck cancer. **J Oncol**. 2009;2009:358098. doi: 10.1155/2009/358098. PubMed PMID: 20169126; PubMed Central PMCID: PMC2821645.

144. **Licitra L**, Zigon G, Gatta G, Sánchez MJ, Berrino F; EUROCARE Working Group.. Human papillomavirus in HNSCC: a European epidemiologic perspective. **Hematol Oncol Clin North Am**. 2008 Dec;22(6):1143-53, vii-viii. doi: 10.1016/j.hoc.2008.10.002. Review. PubMed PMID: 19010264.
145. van Herpen CM, Locati LD, Buter J, Thomas J, Bogaerts J, Lacombe D, de Mulder P, Awada A, **Licitra L**, Bernier J, Vermorken JB. Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982). **Eur J Cancer**. 2008 Nov;44(17):2542-5. doi: 10.1016/j.ejca.2008.08.014. PubMed PMID: 18819792.
146. **Licitra L**, Locati LD, Bossi P. Optimizing approaches to head and neck cancer. Metastatic head and neck cancer: new options. **Ann Oncol**. 2008 Sep;19 Suppl 7:vii200-3. doi: 10.1093/annonc/mdn456. Review. PubMed PMID: 18790949.
147. Negri T, Tamborini E, Dagrada GP, Greco A, Staurengo S, Guzzo M, Locati LD, Carbone A, Pierotti MA, **Licitra L**, Pilotti S. TRK-A, HER-2/neu, and KIT Expression/Activation Profiles in Salivary Gland Carcinoma. **Transl Oncol**. 2008 Sep;1(3):121-8. PubMed PMID: 18795122; PubMed Central PMCID: PMC2533140.
148. Bossi P, Locati LD, **Licitra L**, Tagliabue E. Folate in head and neck squamous cell cancer chemoprevention: purposely left out? **J Clin Oncol**. 2008 Jul 10;26(20):3463; author reply 3463-4. doi: 10.1200/JCO.2008.17.0514. PubMed PMID: 18612165.
149. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, **Licitra L**, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ; Motesanib Thyroid Cancer Study Group.. Motesanib diphosphate in progressive differentiated thyroid cancer. **N Engl J Med**. 2008 Jul 3;359(1):31-42. doi: 10.1056/NEJMoa075853. PubMed PMID: 18596272.
150. Perrone F, Bossi P, **Licitra L**. TP53 mutations in head and neck cancer. **N Engl J Med**. 2008 Mar 13;358(11):1194-5; author reply 1195. PubMed PMID: 18340660.
151. Palazzi M, Tomatis S, Orlandi E, Guzzo M, Sangalli C, Potepan P, Fantini S, Bergamini C, Gavazzi C, **Licitra L**, Scaramellini G, Cantu' G, Olmi P. Effects of treatment intensification on acute local toxicity during radiotherapy for head and neck cancer: prospective observational study validating CTCAE, version 3.0, scoring system. **Int J Radiat Oncol Biol Phys**. 2008 Feb 1;70(2):330-7. PubMed PMID: 17881148.
152. Bossi P, Locati LD, **Licitra L**. Biological agents in head and neck cancer. **Expert Rev Anticancer Ther**. 2007 Nov;7(11):1643-50. Review. PubMed PMID: 18020930.
153. Perrone F, Mariani L, Pastore E, Orsenigo M, Suardi S, Marcomini B, DaRiva L, **Licitra L**, Carbone A, Pierotti MA, Pilotti S. p53 codon 72 polymorphisms in human papillomavirus-negative and human papillomavirus-positive squamous cell carcinomas of the oropharynx. **Cancer**. 2007 Jun 15;109(12):2461-5. PubMed PMID: 17492690.
154. Bossi P, Liberatoscioli C, Bergamini C, Locati LD, Fava S, Rinaldi G, Orlandi E, Olmi P, Tagliabue E, Ménard S, **Licitra L**. Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients. **Ann Oncol**. 2007 Mar;18(3):601-2. PubMed PMID: 17074970.
155. **Licitra L**, Perrone F, Bossi P, Suardi S, Mariani L, Artusi R, Oggionni M, Rossini C, Cantù G, Squadrelli M, Quattrone P, Locati LD, Bergamini C, Olmi P, Pierotti MA, Pilotti S. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. **J Clin Oncol**. 2006 Dec 20;24(36):5630-6. PubMed PMID: 17179101.
156. Perrone F, Suardi S, Pastore E, Casieri P, Orsenigo M, Caramuta S, Dagrada G, Losa M, **Licitra L**, Bossi P, Staurengo S, Oggionni M, Locati L, Cantu G, Squadrelli M, Carbone A, Pierotti MA, Pilotti S. Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. **Clin Cancer Res**. 2006 Nov 15;12(22):6643-51. Erratum in: Clin Cancer Res. 2007 Jul 15;13(14):4313. PubMed PMID: 17121883.
157. Frattini M, Perrone F, Suardi S, Balestra D, Caramuta S, Colombo F, **Licitra L**, Cantù G, Pierotti MA, Pilotti S. Phenotype-genotype correlation: challenge of intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. **Head Neck**. 2006 Oct;28(10):909-15. PubMed PMID: 16906516.

158. **Licitra L**, Locati L, Bossi P. Biological agents in head and neck cancer. **Ann Oncol**. 2006 Sep;17 Suppl 10:x45-8. Review. PubMed PMID: 17018750.
159. **Licitra LF**, Locati LD, Potepan P, Crippa F, Bossi P, Bergamini C, Rinaldi G, Liberatoscioli C, Perrone F, Losa M, Pilotti S. Cetuximab (C225) in recurrent and/or metastatic salivary gland carcinomas (RMSGCs): A monoinstitutional phase II study. **J Clin Oncol**. 2006 Jun 20;24(18\_suppl):5547. PubMed PMID: 27954501.
160. Laurie SA, **Licitra L**. Systemic therapy in the palliative management of advanced salivary gland cancers. **J Clin Oncol**. 2006 Jun 10;24(17):2673-8. Review. PubMed PMID: 16763282.
161. **Licitra L**, Bossi P, Locati LD. A multidisciplinary approach to squamous cell carcinomas of the head and neck: what is new? **Curr Opin Oncol**. 2006 May;18(3):253-7. Review. PubMed PMID: 16552237.
162. **Licitra L**, Rossini C, Bossi P, Locati LD. Advances in the changing patterns of aetiology of head and neck cancers. **Curr Opin Otolaryngol Head Neck Surg**. 2006 Apr;14(2):95-9. Review. PubMed PMID: 16552266.
163. **Licitra L**, Bossi P, Locati LD, Bergamini C. Is restoring platinum sensitivity the best goal for cetuximab in recurrent/metastatic nasopharyngeal cancer? **J Clin Oncol**. 2005 Oct 20;23(30):7757-8; author reply 7758-9. PubMed PMID: 16234549.
164. Locati LD, Guzzo M, Bossi P, Massone PP, Conti B, Fumagalli E, Bareggi C, Cantù G, **Licitra L**. Lung metastasectomy in adenoid cystic carcinoma (ACC) of salivary gland. **Oral Oncol**. 2005 Oct;41(9):890-4. PubMed PMID: 16043380.
165. Cantù G, Solero CL, Miceli R, Mariani L, Mattavelli F, Squadrelli-Saraceno M, Bimbi G, Riccio S, Colombo S, Locati L, Olmi P, **Licitra L**. Which classification for ethmoid malignant tumors involving the anterior skull base? **Head Neck**. 2005 Mar;27(3):224-31. PubMed PMID: 15627260.
166. Locati LD, Rinaldi G, Bossi P, Dagrada GP, Quattrone P, Cantù G, **Licitra L**. Herceptin plus chemotherapy in relapsed and/or metastatic salivary gland cancer. **Oral Oncol**. 2005 Jan;41(1):97-8. PubMed PMID: 15598592.
167. **Licitra L**, Suardi S, Bossi P, Locati LD, Mariani L, Quattrone P, Lo Vullo S, Oggionni M, Olmi P, Cantù G, Pierotti MA, Pilotti S. Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma. **J Clin Oncol**. 2004 Dec 15;22(24):4901-6. PubMed PMID: 15611505.
168. Bimbi G, Saraceno MS, Riccio S, Gatta G, **Licitra L**, Cantù G. Adenocarcinoma of ethmoid sinus: an occupational disease. **Acta Otorhinolaryngol Ital**. 2004 Aug;24(4):199-203. PubMed PMID: 15688904.
169. **Licitra L**, Locati LD, Bossi P, Cantù G. Head and neck tumors other than squamous cell carcinoma. **Curr Opin Oncol**. 2004 May;16(3):236-41. Review. PubMed PMID: 15069319.
170. **Licitra L**, Bossi P, Locati L, Zunino F. Cisplatin and fluorouracil concurrent to radiotherapy in nasopharyngeal cancer: is the schedule compatible? **J Clin Oncol**. 2004 Jan 15;22(2):377; author reply 377-8. PubMed PMID: 14722048.
171. **Licitra L**, Locati LD, Bossi P. Head and neck cancer. **Ann Oncol**. 2004;15 Suppl 4:iv267-73. Review. PubMed PMID: 15477319.
172. **Licitra L**, Vermorken JB. Is there still a role for neoadjuvant chemotherapy in head and neck cancer? **Ann Oncol**. 2004 Jan;15(1):7-11. Review. PubMed PMID: 14679112.
173. Palazzi M, Guzzo M, Bossi P, Tomatis S, Cerrotta A, Cantù G, Locati LD, **Licitra L**. Regionally advanced nasopharyngeal carcinoma: long-term outcome after sequential chemotherapy and radiotherapy. **Tumori**. 2004 Jan-Feb;90(1):60-5. PubMed PMID: 15143974.
174. Sanguineti G, Bossi P, Pou A, **Licitra L**. Timing of chemoradiotherapy and patient selection for locally advanced nasopharyngeal carcinoma. **Clin Oncol (R Coll Radiol)**. 2003 Dec;15(8):451-60. Review. PubMed PMID: 14690000.

175. Locati LD, Quattrone P, Bossi P, Marchianò AV, Cantù G, **Licitra L**. A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. **Ann Oncol**. 2003 Aug;14(8):1327-8. PubMed PMID: 12881399.
176. **Licitra L**, Bernier J, Grandi C, Locati L, Merlano M, Gatta G, Lefebvre JL. Cancer of the larynx. **Crit Rev Oncol Hematol**. 2003 Jul;47(1):65-80. Review. PubMed PMID: 12853099.
177. Perrone F, Oggionni M, Birindelli S, Suardi S, Tabano S, Romano R, Moiraghi ML, Bimbi G, Quattrone P, Cantu G, Pierotti MA, **Licitra L**, Pilotti S. TP53, p14ARF, p16INK4a and H-ras gene molecular analysis in intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. **Int J Cancer**. 2003 Jun 10;105(2):196-203. PubMed PMID: 12673679.
178. **Licitra L**. Chemoradiation therapy in locally advanced nasopharyngeal cancer: which kind of cooperation? **Ann Oncol**. 2003 Apr;14(4):508-9. PubMed PMID: 12649094.
179. **Licitra L**, Locati LD, Cavina R, Garassino I, Mattavelli F, Pizzi N, Quattrone P, Valagussa P, Gianni L, Bonadonna G, Solero CL, Cantu G. Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer. **Ann Oncol**. 2003 Mar;14(3):367-72. PubMed PMID: 12598339.
180. **Licitra L**, Grandi C, Prott FJ, Schornagel JH, Bruzzi P, Molinari R. Major and minor salivary glands tumours. **Crit Rev Oncol Hematol**. 2003 Feb;45(2):215-25. Review. PubMed PMID: 12604131.
181. **Licitra L**, Bernier J, Cvitkovic E, Grandi C, Spinazzé S, Bruzzi P, Gatta G, Molinari R. Cancer of the nasopharynx. **Crit Rev Oncol Hematol**. 2003 Feb;45(2):199-213. Review. PubMed PMID: 12604130.
182. **Licitra L**, Grandi C, Guzzo M, Mariani L, Lo Vullo S, Valvo F, Quattrone P, Valagussa P, Bonadonna G, Molinari R, Cantù G. Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. **J Clin Oncol**. 2003 Jan 15;21(2):327-33. PubMed PMID: 12525526.
183. Drago GP, Setti E, **Licitra L**, Liberati D. Forecasting the performance status of head and neck cancer patient treatment by an interval arithmetic pruned perceptron. **IEEE Trans Biomed Eng**. 2002 Aug;49(8):782-7. PubMed PMID: 12148816.
184. **Licitra L**, Spinazzé S, Roila F. Antiemetic therapy. **Crit Rev Oncol Hematol**. 2002 Jul;43(1):93-101. Review. PubMed PMID: 12098610.
185. Locati LD, Quattrone P, Pizzi N, Fior A, Cantù G, **Licitra L**. Primary high-grade mucoepidermoid carcinoma of the minor salivary glands with cutaneous metastases at diagnosis. **Oral Oncol**. 2002 Jun;38(4):401-4. PubMed PMID: 12076708.
186. Bernier J, Vermorken JB, Debruyne C, Andry G, **Licitra L**, Grandi C, Langendijk H, De Mulder PH, Lefèbvre JL. From chemoprevention and organ preservation programmes to postoperative management: major achievements and strategies of the EORTC Head and Neck Cancer Group. **Eur J Cancer**. 2002 Mar;38 Suppl 4:S75-81. PubMed PMID: 11858970.
187. **Licitra L**, Bernier J, Grandi C, Merlano M, Bruzzi P, Lefebvre JL. Cancer of the oropharynx. **Crit Rev Oncol Hematol**. 2002 Jan;41(1):107-22. Review. PubMed PMID: 11796235.
188. Casali PG, **Licitra L**, Bruzzi P. QUOROM and the search for an updated 'clinical method' in the era of evidence-based medicine. **Ann Oncol**. 2000 Aug;11(8):923-5. PubMed PMID: 11038027.
189. Costantini M, Mencaglia E, Giulio PD, Cortesi E, Roila F, Ballatori E, Tamburini M, Casali P, **Licitra L**, Candis DD, Massidda B, Luzzani M, Campora E, Placido SD, Palmeri S, Angela PM, Baracco G, Gareri R, Martignetti A, Ragosa S, Zoda L, Ionta MT, Bulletti S, Pastore L. Cancer patients as 'experts' in defining quality of life domains. A multicentre survey by the Italian Group for the Evaluation of Outcomes in Oncology (IGEO). **Qual Life Res**. 2000 Mar;9(2):151-9. PubMed PMID: 10983479.

190. Grandi C, Guzzo M, Cavina R, Gardani G, Tana S, **Licitra L**, Rossi N, Barbaccia C, Mingardo M, Fallahdar D, Bruno P, Molinari R. Treatment of cancer of the base of the tongue and glosso-epiglottic region: a multicenter Italian survey. GLOCC Group. Gruppo di Lavoro in Oncologia Cervico Cefalica. **Tumori**. 2000 May-Jun;86(3):215-23. PubMed PMID: 10939602.
191. Cantú G, Solero CL, Mariani L, Mattavelli F, Pizzi N, Licitra L. A new classification for malignant tumors involving the anterior skull base. **Arch Otolaryngol Head Neck Surg**. 1999 Nov;125(11):1252-7. PubMed PMID: 10555698.
192. Casali P, **Licitra L**, Tondini C, de Braud F, Bruzzi P, Costa A, Cavalli F. START: a European state-of-the-art on-line instrument for clinical oncologists. **Ann Oncol**. 1999 Jul;10(7):769-73. PubMed PMID: 10470422.
193. Costa A, **Licitra L**, Veneroni S, Daidone MG, Grandi C, Cavina R, Molinari R, Silvestrini R. Biological markers as indicators of pathological response to primary chemotherapy in oral-cavity cancers. **Int J Cancer**. 1998 Dec 18;79(6):619-23. PubMed PMID: 9842971.
194. Cantù G, Pizzi N, Mattavelli F, Salvatori P, **Licitra L**, Solero CL. [Classification of ethmoid malignancies]. **Acta Otorhinolaryngol Ital**. 1998 Jun;18(3):135-42. Italian. PubMed PMID: 9926446.
195. **Licitra L**, Cavina R, Cerrotta A. The multidisciplinary approach in clinical oncology. **Tumori**. 1998 Mar-Apr;84(2):279-80. PubMed PMID: 9620258.
196. Casali P, **Licitra L**, Costantini M, Santoro A, Viterbori P, Bajetta E, Bruzzi P. Quality of life assessment and clinical decision-making. **Ann Oncol**. 1997 Dec;8(12):1207-11. PubMed PMID: 9496385.
197. **Licitra L**, Capri G, Fulfarò F, Grandi C, Tarenzi E, Cavina R, Gianni L. Biweekly paclitaxel and cisplatin in patients with advanced head and neck carcinoma. A phase II trial. **Ann Oncol**. 1997 Nov;8(11):1157-8. PubMed PMID: 9426337.
198. Costantini M, Mencaglia E, Di Giulio P, Cortesi E, Roila F, Ballatori E, Tamburini M, Casali P, **Licitra L**, Massidda B, Luzzani M, Campora E, De Placido S, Palmeri S, Palladino MA, Baracco G, Gareri R, Martignetti A, Ragosa S, Zoda L, Ionta MT, Bulletti S, Pastore L. [Evaluation of quality of life in oncology. Rationale and objectives of the first phase of the Quality of Life in Oncology project]. **Tumori**. 1997;83(2 Suppl):S25-7. Italian. PubMed PMID: 9235726.
199. **Licitra L**, Cavina R, Grandi C, Palma SD, Guzzo M, Demicheli R, Molinari R. Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. **Ann Oncol**. 1996 Aug;7(6):640-2. PubMed PMID: 8879381.
200. Guzzo M, Grandi C, **Licitra L**, Podrecca S, Cascinelli N, Molinari R. Mucosal malignant melanoma of head and neck: forty-eight cases treated at Istituto Nazionale Tumori of Milan. **Eur J Surg Oncol**. 1993 Aug;19(4):316-9. PubMed PMID: 8359279.
201. Grandi C, Mingardo M, Guzzo M, **Licitra L**, Podrecca S, Molinari R. Salvage surgery of cervical recurrences after neck dissection or radiotherapy. **Head Neck**. 1993 Jul-Aug;15(4):292-5. PubMed PMID: 8360049.
202. **Licitra L**, Marchini S, Spinazzè S, Rossi A, Rocca A, Grandi C, Molinari R. Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients. **Cancer**. 1991 Nov 1;68(9):1874-7. Review. PubMed PMID: 1913539.
203. Casali P, **Licitra L**, Alafaci E, Gennari L. [Adjuvant chemotherapy of colorectal carcinoma]. **Ann Ital Chir**. 1990 Sep-Oct;61(5):509-13. Review. Italian. PubMed PMID: 2100969.

**Capitoli di volumi a stampa, in inglese:**

1. Laura D. Locati, Marco Guzzo, Ester Orlandi, **Lisa Licitra**. Management of Salivary Gland Cancer in "Head and Neck Cancer: Multimodality Management, 2nd edition" by Jacques Bernier English | ISBN: 3319275992 | 2016
2. **Licitra L**, Vermorken JB, Specenier P, Caraceni A. Systemic Therapy in the Treatment of Recurrent and Metastatic Head and Neck Carcinoma' in Head and Neck Cancer Recurrence, Evidence-based, Multidisciplinary Management by Mehanna HM, Kian Ang K New York, Thieme 2012.
3. **Licitra L**, Locati L, Bergamini C and Bossi P. Role of HPV Infection in Head and Neck Cancer. in: Multidisciplinary Management of Head and Neck Cancer by Haddad RI: Demos Medical; 1 edition (November 23, 2010).

4. **Licitra L**, Bossi P, Locati L, Cantù G, Olmi P. Oropharyngeal Cancer. In: Chief Editor Chris de Souza. Head and Neck Surgery. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd. 209. p. 970-7.
5. **Licitra L**, Bossi P, Locati L, Cantù G, Olmi P. Oropharyngeal cancers. In: Cavalli F, Hansen HH, Kaye SB, editors. Textbook of Medical Oncology. 4th ed. Taylor & Francis. 2009.
6. Schrijvers D, **Licitra L**. Head and Neck Cancer. In: Cavalli F, Hansen HH, Kaye SB, editors. Textbook of Medical Oncology. 4th ed. Taylor & Francis. 2009. .
7. **Licitra L**, Vermorken JB, Specenier P, Caraceni A. Systemic Therapy in the Treatment of Recurrent and Metastatic Head and Neck Carcinoma' in Head and Neck Cancer Recurrence, Evidence-based, Multidisciplinary Management by Mehanna HM, Kian Ang K New York, Thieme 2012.
8. **Licitra L**, Locati L, Bergamini C and Bossi P. Role of HPV Infection in Head and Neck Cancer. in: Multidisciplinary Management of Head and Neck Cancer by Haddad RI: Demos Medical; 1 edition (November 23, 2010).
9. Schrijvers D, **Licitra L**. Head and Neck Cancer. In: Cavalli F, Hansen HH, Kaye SB, editors. Textbook of Medical Oncology. 4th ed. Taylor & Francis. 2009.
10. Schrijvers D, **Licitra L**. Head and Neck Cancer. In: Cavalli F, Hansen HH, Kaye SB, editors. Textbook of Medical Oncology. 3rd ed. Taylor & Francis. 2004.

#### **Volumi a stampa, in italiano:**

1. **Licitra L**, Olmi P (a cura di). Tumori della testa e del collo. Integrazione terapeutica nella conservazione della funzione d'organo. Milano, **Springer – Verlag**, 2011.
2. **Casali P**, Licitra L, Santoro A. Metodologia Clinica in Oncologia. *Napoli, Società Editrice Scientifica; 1991*

#### **Capitoli di volumi a stampa, in italiano:**

1. **Licitra L**, Cantù G, Olmi P,. Neoplasie del Distretto cervico-Facciale. In: Bonadonna G, Robustelli della Cuna G, Valagussa P, Editors. Medicina Oncologica. 8° ed. Elsevier – Masson. 2007.
2. **Licitra L** et al. Tumori della Testa e del Collo. In: Cavalli F., Cognetti F., Costa A., Orecchia R. (a cura di), Fondamenti di Oncologia clinica, Elsevier, Milano, 2006.
3. **Licitra L**, Cantù G, Olmi P. Neoplasie del Distretto cervico-Facciale. In: Bonadonna G, Robustelli della Cuna G, Valagussa P, Editors. Medicina Oncologica. 7° ed. Elsevier – Masson. 2003.
4. Casali PG, **Licitra L**. Il cancro: aspetti clinici. In: Psiconcologia. Bellani ML, Morasso G, Amadori D, Orrù W, Grassi L, Casali PG, Bruzzi P (eds.), Milano: Masson; 2002.
5. **Licitra L**, Mencaglia M. Qualità di vita nei sarcomi. In: I Sarcomi. Santoro A. (ed.), Pavia, Edizioni Medico-Scientifiche; Advances in Clinical Oncology - Progressi in Oncologia Clinica (Robustelli della Cuna G, Ed.), 4: 1994.
6. Cognetti F, **Licitra L**. Tumori del distretto cervico-facciale. In: Terapia Medica Oncologica 1992. Bonadonna G, Santoro A (eds). Napoli, Società Editrice Scientifica; 1992.
7. **Licitra L**, Casali P. Tumori rari. In: Terapia Medica Oncologica 1992. Bonadonna G, Santoro A (eds). Napoli, Società Editrice Scientifica, 1992.
8. Cognetti F, **Licitra L**. Tumori del distretto cervico-facciale. In: Terapia Medica Oncologica. Bonadonna G, Santoro A (eds) Napoli, Società Editrice Scientifica; 1990.
9. **Licitra L**. Bilancio dell'attività dei farmaci chemioterapici e loro associazioni. In: I tumori della Testa e del Collo. Veronesi U, Molinari R, Banfi A, Santoro A (eds). Milano, Ambrosiana Editrice, 1990.
10. Morandi F, **Licitra L**, Gasparini M. Chemioterapia preoperatoria nell'osteosarcoma. In: Radioterapia e Trattamenti Integrati. Banfi, Lattuada, Santoro A, Zucali (eds); Milano, Ambrosiana Editrice, 1988.
11. Monfardini S, **Licitra L**. Terapie combinate del carcinoma esofageo. In: Neoplasie del Torace. Veronesi, Pezzuoli, Ravasi, Santoro A (eds), Milano, Ambrosiana Editrice; 1986.